drugset / Trial / NCT01271283
Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase II clinical trial is studying how well lenalidomide works in treating patients with high-risk chronic lymphocytic leukemia. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing.
Timeline
- Start
- 2010-12
- Primary completion
- 2011-08
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | — | Oral |